MAPT and Alzheimer disease: For instance, M.I. Diamond’s lab used the first generation of FRET biosensors to demonstrate that tau proteopathic seeding correlates with the pathology progression and can be detected before the appearance of classical histopathological markers in both P301S mice and patients with AD [92,104,105].